Category: Federal Forum Posters
Purpose: Metabolic side effects such as weight gain, alterations in glucose metabolism, and lipid abnormalities, have been associated with the use of antipsychotic medications. These alterations can lead to cardiovascular disease and earlier mortality. Lurasidone is thought to have a lower metabolic risk than many other antipsychotics but there is a lack of epidemiologic data supporting this conclusion. The objective of this study is to evaluate the metabolic risk associated with lurasidone and to educate healthcare practitioners on findings to encourage monitoring as applicable.
Methods: The electronic medical record system was used to identify patients who were initiated or maintained on lurasidone between the dates of July 1, 2017 until July 1, 2018. The following data was collected: patient age, gender, diagnosis, weight, lipid panel, and hemoglobin A1C. We also collected data on refills to assess patient adherence. Data points were collected prior to the initiation of therapy (baseline) and post initiation of therapy. All data were recorded without patient identifiers to maintain confidentially. Patients who were not on lurasidone for at least three months were excluded from the study. Following data collection, the information was analyzed to determine the metabolic effect of lurasidone on patients.
Results: Not applicable
Conclusion: Not applicable
Brittany Dickhaus– PGY1 Pharmacy Resident, Veterans Affairs Connecticut Healthcare System, East Haven, CT